Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27410500 | 0.97 | STK17B (0.45) | STK17BSTK17AFGFR1FGFR4DOT1L | |
| SCHEMBL4644008 | 0.96 | DRD2 (0.45) | STK17BSTK17AFGFR1FGFR4DOT1L | |
| SCHEMBL4640082 | 0.93 | FGFR1 (0.47) | STK17BSTK17AFGFR1FGFR4DOT1L | |
| SCHEMBL22359200 | 0.83 | ADCY5 (0.57) | FGFR1DOT1LADCY5 | |
| SCHEMBL26348187 | 0.83 | STK17B (0.49) | STK17BSTK17AHDAC6P2RX7DRD2 | |
| SCHEMBL21591519 | 0.82 | FGFR1 (0.51) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL6805557 | 0.80 | P2RX7 (0.48) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL17297735 | 0.80 | PI4KA (0.55) | FGFR1DOT1LADCY5 | |
| SCHEMBL17150783 | 0.79 | P2RX7 (0.45) | STK17BSTK17AHDAC6P2RX7DRD2 | |
| SCHEMBL12049642 | 0.78 | FGFR1 (0.58) | FGFR1FGFR4HDAC6P2RX7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | STK17B 1120/4885STK17A 996/4885FGFR1 2759/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | STK17B 1120/4885STK17A 996/4885FGFR1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.